SCHEMBL10241710

SCHEMBL10241710

Cc1cc2c(cc1O)[nH]c1ccccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 1/20 0.61
KDM4E B2RXH2 5/20 0.60
MAPT P10636 4/20 0.60
ATM Q13315 1/20 0.60
KIF11 P52732 7/20 0.56
ALDH1A1 P00352 5/20 0.52
HSD17B10 Q99714 3/20 0.52
GPR3 P46089 1/20 0.52
SRC P12931 1/20 0.48
PRKACA P17612 1/20 0.48
PRKACG P22612 1/20 0.48
PRKACB P22694 1/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
HPGD P15428 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C19 P33261 1/20 0.47
TNKS2 Q9H2K2 1/20 0.47
IMPDH2 P12268 1/20 0.47
IMPDH1 P20839 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29885265 0.93 AHR (0.61) AHRKDM4EMAPTATMKIF11
SCHEMBL27800010 0.84 AHR (0.71) AHRKDM4EMAPTATMKIF11
SCHEMBL3884246 0.84 AHR (0.71) AHRKDM4EMAPTATMKIF11
SCHEMBL20434618 0.81 KIF11 (0.56) KDM4EMAPTATMKIF11ALDH1A1
SCHEMBL18490722 0.81 KDM4E (0.56) KDM4EMAPTATMKIF11ALDH1A1
SCHEMBL23165814 0.78 AHR (0.61) AHRKDM4EMAPTATMKIF11
SCHEMBL29760324 0.78 AHR (0.61) AHRKDM4EMAPTATMKIF11
SCHEMBL14607152 0.78 AHR (0.61) AHRKDM4EMAPTATMKIF11
SCHEMBL3876929 0.78 AHR (0.61) AHRKDM4EMAPTATMKIF11
SCHEMBL12789830 0.77 KIF11 (0.56) AHRKDM4EMAPTATMKIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118141926-A Application of plant carbazole alkaloid in preparation of iron death inhibitor 北京大学 2024-06-07 CN disclosed
US-20230217813-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE DEVICE, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC APPARATUS IDEMITSU KOSAN CO.,LTD. (JP) 2023-07-06 US disclosed
EP-3229811-B1 PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS GRI BIO INC (US) 2021-02-24 EP disclosed
WO-2016094226-A1 PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS GLYCOREGIMMUNE, INC. (US) 2016-06-16 WO disclosed
US-20160158258-A1 PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS ALTIUM GROWTH FUND, LP 2016-06-09 US disclosed
US-8263657-B2 Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-09-11 US disclosed
US-8263657-B2 Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-09-11 US disclosed
US-8097759-B2 Inflammatory cytokine release inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-01-17 US disclosed
US-8097759-B2 Inflammatory cytokine release inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-01-17 US disclosed
US-20110059953-A1 COMPOUNDS FOR USE IN STABILIZING P53 MUTANTS MEDICAL RESEARCH COUNCIL (GB) 2011-03-10 US disclosed
US-20080090779-A1 ANTIALLERGIC AGENTS INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-04-17 US disclosed
US-20080090779-A1 ANTIALLERGIC AGENTS INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-04-17 US disclosed
EP-1847263-A2 Inhibitors against the production and release of inflammatory cytokines Institute of Medicinal Molecular Design, Inc. (JP) 2007-10-24 EP disclosed
EP-1844766-A2 Inhibitors against the production and release of inflammatory cytokines Institute of Medicinal Molecular Design, Inc. (JP) 2007-10-17 EP disclosed
US-20070185059-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US disclosed
US-20070185059-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US disclosed
US-20070185110-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US disclosed
US-20070185110-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US disclosed
US-20070042997-A1 Medicament for treatment of dermal pigmentation INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-02-22 US disclosed
US-20070042997-A1 Medicament for treatment of dermal pigmentation INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090779-A1 ANTIALLERGIC AGENTS NAT1, EPX, HRH2 AHR 4/4885KDM4E 1835/4885MAPT 2536/4885
US-20110059953-A1 COMPOUNDS FOR USE IN STABILIZING P53 MUTANTS TP53, TP53BP1, MDM2 AHR 1802/4885KDM4E 4428/4885MAPT 4400/4885
US-20230217813-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE DEVICE, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC APPARATUS L1CAM, LEF1, PIEZO1 AHR 619/4885KDM4E 3203/4885MAPT 1580/4885
US-20070185110-A1 Antiallergic agents NAT1, EPX, AHR AHR 3/4885KDM4E 1821/4885MAPT 2469/4885
US-20070185059-A1 Antiallergic agents NAT1, EPX, AHR AHR 3/4885KDM4E 1698/4885MAPT 2415/4885
US-20070042997-A1 Medicament for treatment of dermal pigmentation TYR, XDH, XPA AHR 26/4885KDM4E 2305/4885MAPT 3082/4885
US-20160158258-A1 PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS RXRA, RXRG, CX3CR1 AHR 1120/4885KDM4E 812/4885MAPT 4762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.